Scholarlink

<p>Waldenström macroglobulinemia (WM) is a rare indolent neoplasm characterized by presence of ≥ 10% lymphoid cells in the BM exhibiting plasmacytoid or plasma-cell differentiation, with secretion of an IgM monoclonal protein. This is a retrospective analysis of 89 patients with WM that describes the clinical and laboratory characteristics, treatment patterns and outcome of patients with WM. The median age of the entire cohort was 66 years with male predominance (67.4%). Most common presentations were symptoms pertaining to anemia (77.5%) and constitutional symptoms (33.7%). Median bone marrow lymphoplasmacytic cells were 41%. Positivity for MYD88 and CXCR4 mutations was seen in 81.8% of 77 and 2.4% of 41 tested patients, respectively. BR was the most common regimen used (52.8%). The overall response rate was 87.8%. Median overall survival, progression-free survival and time to next treatment were 8.49, 2.15 and 3.88 years, respectively. BR was associated with the longest observed progression-free survival in this cohort.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinico-Pathologic Characteristics, Patterns of Treatment and Outcome of Newly Diagnosed Waldenstroms Macroglobulinemia- A Single Center Real World Retrospective Analysis

  • 期刊论文

  • 发表日期：

    2026年7月14日

查看全文
  • Vaibhav Gupta,
  • Dibakar Podder,
  • Saswata Saha,
  • Bikash Shah,
  • Shouriyo Ghosh,
  • Jeevan Kumar,
  • Arjin Philips Jacoby,
  • Arijit Nag,
  • Debranjani Chattyopadhyay,
  • Rizwan Javed,
  • Ashish Rath,
  • Subhosmito Chakraborty,
  • Rakesh Demde,
  • Sushant Vinarkar,
  • Mayur Parihar,
  • Lateef Zameer,
  • Deepak Mishra,
  • Mammen Chandy,
  • Reena Nair

摘要

Waldenström macroglobulinemia (WM) is a rare indolent neoplasm characterized by presence of ≥ 10% lymphoid cells in the BM exhibiting plasmacytoid or plasma-cell differentiation, with secretion of an IgM monoclonal protein. This is a retrospective analysis of 89 patients with WM that describes the clinical and laboratory characteristics, treatment patterns and outcome of patients with WM. The median age of the entire cohort was 66 years with male predominance (67.4%). Most common presentations were symptoms pertaining to anemia (77.5%) and constitutional symptoms (33.7%). Median bone marrow lymphoplasmacytic cells were 41%. Positivity for MYD88 and CXCR4 mutations was seen in 81.8% of 77 and 2.4% of 41 tested patients, respectively. BR was the most common regimen used (52.8%). The overall response rate was 87.8%. Median overall survival, progression-free survival and time to next treatment were 8.49, 2.15 and 3.88 years, respectively. BR was associated with the longest observed progression-free survival in this cohort.